Association of C1q-fixing DSA with late graft failure in pediatric renal transplant recipients

Pediatric Nephrology

Volumn 31, Issue 7, 2016, Pages 1157-1166

  Fichtner, Alexander ^a   Süsal, Caner ^b   Höcker, Britta ^a   Rieger, Susi ^a   Waldherr, Rüdiger ^c   Westhoff, Jens H ^a   Sander, Anja ^b   Opelz, Gerhard ^b   Tönshoff, Burkhard ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Department of Orthopaedic Surgery   (Germany)

Author keywords

C1q binding donor specific antibodies; Donor specific antibodies; Graft failure; Indication biopsy; Pediatrics; Renal transplantation

Indexed keywords

COMPLEMENT BINDING DONOR SPECIFIC HLA ANTIBODY; COMPLEMENT COMPONENT C1Q; CYCLOSPORIN; HLA ANTIBODY; IMMUNOGLOBULIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLATE MOFETIL; PREDNISOLONE; RITUXIMAB; TACROLIMUS; UNCLASSIFIED DRUG; ANTIBODY; HLA ANTIGEN;

ARTICLE; CHILD; DIAGNOSTIC VALUE; FEMALE; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; ADOLESCENT; COHORT ANALYSIS; COMPLEMENT ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAFT REJECTION; IMMUNOLOGY; RETROSPECTIVE STUDY;

ADOLESCENT; ANTIBODIES; CHILD; COHORT STUDIES; COMPLEMENT ACTIVATION; COMPLEMENT C1Q; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT REJECTION; HLA ANTIGENS; HUMANS; KIDNEY TRANSPLANTATION; MALE; PROGNOSIS; RETROSPECTIVE STUDIES; TRANSPLANT RECIPIENTS;

EID: 84959321425     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-016-3322-8     Document Type: Article

References (29)

1. Einecke G, Sis B, Reeve J, Mengel M, Campbell PM, Hidalgo LG, Kaplan B, Halloran PF (2009) Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 9:2520–2531
2. Lee PC, Zhu L, Terasaki PI, Everly MJ (2009) HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation 88:568–574
3. Chaudhuri A, Ozawa M, Everly MJ, Ettenger R, Dharnidharka V, Benfield M, Mathias R, Portale A, McDonald R, Harmon W, Kershaw D, Vehaskari VM, Kamil E, Baluarte HJ, Warady B, Li L, Sigdel TK, Hsieh SC, Dai H, Naesens M, Waskerwitz J, Salvatierra O Jr, Terasaki PI, Sarwal MM (2013) The clinical impact of humoral immunity in pediatric renal transplantation. J Am Soc Nephrol 24:655–664
4. Gaston RS, Cecka JM, Kasiske BL, Fieberg AM, Leduc R, Cosio FC, Gourishankar S, Grande J, Halloran P, Hunsicker L, Mannon R, Rush D, Matas AJ (2010) Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 90:68–74
5. Sellares J, de Freitas DG, Mengel M, Reeve J, Einecke G, Sis B, Hidalgo LG, Famulski K, Matas A, Halloran PF (2012) Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 12:388–399
6. Everly MJ, Rebellato LM, Haisch CE, Ozawa M, Parker K, Briley KP, Catrou PG, Bolin P, Kendrick WT, Kendrick SA, Harland RC, Terasaki PI (2013) Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation 95:410–417
7. Gupta G, Abu Jawdeh BG, Racusen LC, Bhasin B, Arend LJ, Trollinger B, Kraus E, Rabb H, Zachary AA, Montgomery RA, Alachkar N (2014) Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies. Transplantation 97:1240–1246
8. Gosset C, Lefaucheur C, Glotz D (2014) New insights in antibody-mediated rejection. Curr Opin Nephrol Hypertens 23:597–604
9. Tait BD, Susal C, Gebel HM, Nickerson PW, Zachary AA, Claas FH, Reed EF, Bray RA, Campbell P, Chapman JR, Coates PT, Colvin RB, Cozzi E, Doxiadis II, Fuggle SV, Gill J, Glotz D, Lachmann N, Mohanakumar T, Suciu-Foca N, Sumitran-Holgersson S, Tanabe K, Taylor CJ, Tyan DB, Webster A, Zeevi A, Opelz G (2013) Consensus guidelines on the testing and clinical management issues associated with HLA and nonHLA antibodies in transplantation. Transplantation 95:19–47
10. Wiebe C, Gibson IW, Blydt-Hansen TD, Karpinski M, Ho J, Storsley LJ, Goldberg A, Birk PE, Rush DN, Nickerson PW (2012) Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 12:1157–1167
11. Bartel G, Regele H, Wahrmann M, Huttary N, Exner M, Horl WH, Bohmig GA (2008) Posttransplant HLA alloreactivity in stable kidney transplant recipients-incidences and impact on long-term allograft outcomes. Am J Transplant 8:2652–2660
12. Loupy A, Lefaucheur C, Vernerey D, Prugger C, Duong van Huyen JP, Mooney N, Suberbielle C, Fremeaux-Bacchi V, Mejean A, Desgrandchamps F, Anglicheau D, Nochy D, Charron D, Empana JP, Delahousse M, Legendre C, Glotz D, Hill GS, Zeevi A, Jouven X (2013) Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 369:1215–1226
13. Susal C, Wettstein D, Dohler B, Morath C, Ruhenstroth A, Scherer S, Tran TH, Gombos P, Schemmer P, Wagner E, Fehr T, Zivcic-Cosic S, Balen S, Weimer R, Slavcev A, Bosmuller C, Norman DJ, Zeier M, Opelz G, Report ACTS (2015) Association of kidney graft loss with De novo produced donor-specific and Non-donor-specific HLA antibodies detected by single antigen testing. Transplantation 99:1976–1980
14. Sutherland SM, Chen G, Sequeira FA, Lou CD, Alexander SR, Tyan DB (2012) Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant 16:12–17
15. Guidicelli G, Guerville F, Lepreux S, Wiebe C, Thaunat O, Dubois V, Visentin J, Bachelet T, Morelon E, Nickerson P, Merville P, Taupin JL, Couzi L (2015) Non-complement-binding De novo donor-specific anti-HLA antibodies and kidney allograft survival. J Am Soc Nephrol. doi:10.1681/ASN.2014040326
16. Yabu JM, Higgins JP, Chen G, Sequeira F, Busque S, Tyan DB (2011) C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation 91:342–347
17. Yell M, Muth BL, Kaufman DB, Djamali A, Ellis TM (2015) C1q binding activity of De novo donor-specific HLA antibodies in renal transplant recipients with and without antibody-mediated rejection. Transplantation 99:1151–1155
18. Freitas MC, Rebellato LM, Ozawa M, Nguyen A, Sasaki N, Everly M, Briley KP, Haisch CE, Bolin P, Parker K, Kendrick WT, Kendrick SA, Harland RC, Terasaki PI (2013) The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation 95:1113–1119
19. Schaub S, Honger G, Koller MT, Liwski R, Amico P (2014) Determinants of C1q binding in the single antigen bead assay. Transplantation 98:387–393
20. Dharnidharka VR, Fiorina P, Harmon WE (2014) Kidney transplantation in children. N Engl J Med 371:549–558
21. Billing H, Rieger S, Susal C, Waldherr R, Opelz G, Wuhl E, Tonshoff B (2012) IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up. Transpl Int 25:1165–1173
22. Sis B, Mengel M, Haas M, Colvin RB, Halloran PF, Racusen LC, Solez K, Baldwin WM 3rd, Bracamonte ER, Broecker V, Cosio F, Demetris AJ, Drachenberg C, Einecke G, Gloor J, Glotz D, Kraus E, Legendre C, Liapis H, Mannon RB, Nankivell BJ, Nickeleit V, Papadimitriou JC, Randhawa P, Regele H, Renaudin K, Rodriguez ER, Seron D, Seshan S, Suthanthiran M, Wasowska BA, Zachary A, Zeevi A (2010) Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 10:464–471
23. Ginevri F, Nocera A, Comoli P, Innocente A, Cioni M, Parodi A, Fontana I, Magnasco A, Nocco A, Tagliamacco A, Sementa A, Ceriolo P, Ghio L, Zecca M, Cardillo M, Garibotto G, Ghiggeri GM, Poli F (2012) Posttransplant de novo donor-specific hla antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection. Am J Transplant 12:3355–3362
24. Otten HG, Verhaar MC, Borst HP, Hene RJ, van Zuilen AD (2012) Pretransplant donor-specific HLA class-I and -II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant 12:1618–1623
25. Lachmann N, Todorova K, Schulze H, Schonemann C (2013) Systematic comparison of four cell- and Luminex-based methods for assessment of complement-activating HLA antibodies. Transplantation 95:694–700
26. Husain S, Sis B (2013) Advances in the understanding of transplant glomerulopathy. Am J Kidney Dis 62:352–363
27. Hirai T, Furusawa M, Omoto K, Ishida H, Tanabe K (2014) Analysis of predictive and preventive factors for de novo DSA in kidney transplant recipients. Transplantation 98:443–450
28. Nickerson PW, Rush DN (2013) Rejection: an integrated response. Am J Transplant 13:2239–2240
29. Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629–637